tiprankstipranks
Trending News
More News >
Advertisement
Advertisement

Atai Life Sciences price target lowered to $11 from $12 at Canaccord

Canaccord lowered the firm’s price target on Atai Life Sciences (ATAI) to $11 from $12 and keeps a Buy rating on the shares. The firm noted they announced that inidascamine (formerly RL-007), a non-psychedelic, did not meet its primary endpoint in a Phase 2b trial for cognitive impairment associated with schizophrenia (CIAS), but showed some numerical improvements on cognitive and functional scores. Canaccord believes the weakness presents a solid oportunity to buy the shares on a more streamlined focus.

Elevate Your Investing Strategy:

  • Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

Disclaimer & DisclosureReport an Issue

1